STOCKHOLM, SWEDEN--(Marketwire - August 31, 2010) -
The total number of shares in Swedish Orphan Biovitrum AB (publ) as per August 31, 2010 amounts to 212,696,864 shares, whereof 212,181,279 common shares and 515,585 class C shares[1], corresponding to in total 212,232,837.5 votes. The increase in the number of shares and votes results from a directed issue of 282,425 common shares, constituting milestone payment to certain vendors of Arexis AB.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer supportive care and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com.
For more information please contact: Swedish Orphan Biovitrum AB (publ): Göran Arvidson, CFO Phone: +46 8 697 23 68 E-mailGoran.Arvidson@sobi.com Erik Kinnman, Investor Relations & Public Affairs Phone: +46 8 697 21 50 E-mail:Erik.Kinnman@sobi.com
Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on August 31, 2010 at 3:30 p.m. CET.
[1] All class C shares are held by Swedish Orphan Biovitrum.
[HUG#1441650]
Press release in PDF format : http://hugin.info/134557/R/1441650/385949.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
